Floatz logo

Natalizumab

Relapsing Forms of Multiple Sclerosis

BiogenEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

183 Active assets in the Relapsing Forms of Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB

View all 50 →

Same molecule, other indications

Natalizumab is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
79 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →
secondary progressive multiple sclerosisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →